We, therefore, designed this review to explore all evidence-based articles that pertain to the use of this novel drug (aldosterone synthase inhibitor) in the treatment of cardiovascular disease with special emphasis on systemic and resistant HTN. Here, CYP11B2 is linked to cardiovascular disorder.